ELI LILLY & Co is 688.9x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($1.093 T vs $1.59 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SNDX | LLY |
|---|---|---|
| Market cap | $1.59 B | $1.093 T |
| US-listed rank | #2289 | #11 |
| Revenue (latest FY) | $172.35M | $65.18B |
| Net income (latest FY) | -$285.40M | $20.64B |
| Net margin | -165.6% | 31.7% |
| P/E (trailing FY) | - | 53.0 |
| SEC filings | 636 | 989 |
ELI LILLY & Co is 688.9x more valuable than Syndax Pharmaceuticals Inc by market capitalization ($1.093 T vs $1.59 B).
In their latest fiscal years, Syndax Pharmaceuticals Inc reported $172.35M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Syndax Pharmaceuticals Inc and ELI LILLY & Co, or browse the full rankings.